Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi

suck pdf from helios

10.1111/ajt.15929

http://scihub22266oqcxt.onion/10.1111/ajt.15929
suck pdf from google scholar
32301155!ä!32301155
PDF vom PMID32301155  :  Publisher
PDF vom PMID32301155

suck abstract from ncbi

pmid32301155
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • COVID-19 in solid organ transplant recipients: A single-center case series from Spain #MMPMID32301155
  • Fernandez-Ruiz M; Andres A; Loinaz C; Delgado JF; Lopez-Medrano F; San Juan R; Gonzalez E; Polanco N; Folgueira MD; Lalueza A; Lumbreras C; Aguado JM
  • Am J Transplant 2020[Jul]; 20 (7): 1849-1858 PMID32301155show ga
  • The clinical characteristics, management, and outcome of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) after solid organ transplant (SOT) remain unknown. We report our preliminary experience with 18 SOT (kidney [44.4%], liver [33.3%], and heart [22.2%]) recipients diagnosed with COVID-19 by March 23, 2020 at a tertiary-care center at Madrid. Median age at diagnosis was 71.0 +/- 12.8 years, and the median interval since transplantation was 9.3 years. Fever (83.3%) and radiographic abnormalities in form of unilateral or bilateral/multifocal consolidations (72.2%) were the most common presentations. Lopinavir/ritonavir (usually associated with hydroxychloroquine) was used in 50.0% of patients and had to be prematurely discontinued in 2 of them. Other antiviral regimens included hydroxychloroquine monotherapy (27.8%) and interferon-beta (16.7%). As of April 4, the case-fatality rate was 27.8% (5/18). After a median follow-up of 18 days from symptom onset, 30.8% (4/13) of survivors developed progressive respiratory failure, 7.7% (1/13) showed stable clinical condition or improvement, and 61.5% (8/13) had been discharged home. C-reactive protein levels at various points were significantly higher among recipients who experienced unfavorable outcome. In conclusion, this frontline report suggests that SARS-CoV-2 infection has a severe course in SOT recipients.
  • |*Organ Transplantation[MESH]
  • |*Transplant Recipients[MESH]
  • |Aged[MESH]
  • |Antiviral Agents/administration & dosage[MESH]
  • |Betacoronavirus[MESH]
  • |COVID-19[MESH]
  • |Coronavirus Infections/*complications/*mortality/*therapy[MESH]
  • |Drug Combinations[MESH]
  • |Female[MESH]
  • |Fever[MESH]
  • |Humans[MESH]
  • |Hydroxychloroquine/administration & dosage[MESH]
  • |Immunosuppressive Agents/administration & dosage/adverse effects[MESH]
  • |Interferon-beta/administration & dosage[MESH]
  • |Lopinavir/administration & dosage[MESH]
  • |Male[MESH]
  • |Middle Aged[MESH]
  • |Pandemics[MESH]
  • |Pneumonia, Viral/*complications/*mortality/*therapy[MESH]
  • |Radiography, Thoracic[MESH]
  • |Retrospective Studies[MESH]
  • |Ritonavir/administration & dosage[MESH]
  • |SARS-CoV-2[MESH]
  • |Spain/epidemiology[MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    1849 7.20 2020